Clinical trial
A Multicenter, Prospective, Double-Blind, Randomized, Placebo-Controlled, Phase 3 Study of ANG-3777 (Formerly BB3) to Improve Graft Function and Reduce the Severity of Kidney Dysfunction or Delayed Graft Function Following Kidney Transplantation in Recipients of a Deceased Donor Kidney
NCT02474667 is registered in ClinicalTrials.gov with Angion Biomedica Corp as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Multicenter, Prospective, Double-Blind, Randomized, Placebo-Controlled, Phase 3 Study of ANG-3777 (Formerly BB3) to Improve Graft Function and Reduce the Severity of Kidney Dysfunction or Delayed Graft Function Following Kidney Transplantation in Recipients of a Deceased Donor Kidney
- Lead sponsor
- Angion Biomedica Corp
- Phase
- Phase 3
- Overall status
- Unknown status
- Start date
- March 31, 2016
- Completion date
- September 30, 2021
- Enrollment
- 253 (actual)
- Sites
- 30
Conditions
As the registry lists them; a condition with its own page is linked.